B.O.S.S. Retirement Advisors LLC Sells 21,638 Shares of AbbVie Inc. (NYSE:ABBV)

B.O.S.S. Retirement Advisors LLC lowered its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 90.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,367 shares of the company's stock after selling 21,638 shares during the period. B.O.S.S. Retirement Advisors LLC's holdings in AbbVie were worth $421,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ABBV. GGM Financials LLC boosted its stake in AbbVie by 0.7% during the 3rd quarter. GGM Financials LLC now owns 6,895 shares of the company's stock valued at $1,362,000 after purchasing an additional 50 shares in the last quarter. Pine Haven Investment Counsel Inc lifted its holdings in shares of AbbVie by 0.3% in the third quarter. Pine Haven Investment Counsel Inc now owns 18,102 shares of the company's stock valued at $3,575,000 after buying an additional 52 shares during the period. Dillon & Associates Inc. boosted its stake in AbbVie by 0.8% during the third quarter. Dillon & Associates Inc. now owns 6,914 shares of the company's stock valued at $1,362,000 after buying an additional 52 shares in the last quarter. First Citizens Financial Corp grew its holdings in AbbVie by 0.9% during the third quarter. First Citizens Financial Corp now owns 5,777 shares of the company's stock worth $1,141,000 after acquiring an additional 53 shares during the period. Finally, Sunflower Bank N.A. grew its holdings in AbbVie by 0.4% during the third quarter. Sunflower Bank N.A. now owns 13,723 shares of the company's stock worth $2,710,000 after acquiring an additional 53 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares of the company's stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.25% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ABBV shares. TD Cowen raised their price objective on shares of AbbVie from $195.00 to $225.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Bank of America restated a "neutral" rating and set a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Barclays upped their price target on AbbVie from $200.00 to $212.00 and gave the company an "overweight" rating in a report on Monday, October 7th. Morgan Stanley reduced their price objective on AbbVie from $231.00 to $224.00 and set an "overweight" rating for the company in a research note on Tuesday, November 12th. Finally, Leerink Partnrs raised AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Friday, November 22nd. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average target price of $205.50.

AbbVie Stock Down 0.4 %

NYSE ABBV traded down $0.62 during trading on Friday, reaching $170.05. The company's stock had a trading volume of 5,584,343 shares, compared to its average volume of 4,522,214. The business has a 50-day moving average price of $175.84 and a 200-day moving average price of $184.77. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $207.32. The stock has a market capitalization of $300.51 billion, a PE ratio of 59.05, a PEG ratio of 1.68 and a beta of 0.58. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.92 by $0.08. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business's revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company earned $2.95 earnings per share. On average, research analysts forecast that AbbVie Inc. will post 10.06 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $1.64 dividend. The ex-dividend date is Wednesday, January 15th. This is a positive change from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 dividend on an annualized basis and a yield of 3.86%. AbbVie's dividend payout ratio (DPR) is presently 227.78%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.